遗传性乳腺癌诊断不足:基因检测指南是工具还是障碍?
这项多中心前瞻性注册研究纳入959例乳腺癌患者,评估NCCN指南识别携带致病性变异患者的能力。49.95%符合NCCN标准,50.05%不符合;符合者中9.39%携带致病/可能致病变异,不符合者中7.9%携带,差异无统计学意义(Fisher精确检验P=0.4241)。作者建议所有乳腺癌患者接受扩大panel检测。
要点
- 符合与不符合NCCN指南的患者中致病/可能致病变异检出率无显著差异(9.39% vs 7.9%,P=0.4241)。
- 近半数携带可干预致病/可能致病变异的乳腺癌患者被现行检测指南漏检。
- 作者建议所有确诊乳腺癌的患者接受扩大panel检测。
核心结论
- 近半数携带具有临床可操作性或管理指南制定中的致病/可能致病变异的乳腺癌患者被现行检测指南漏检。
- 作者建议所有确诊乳腺癌的患者接受扩大panel检测。
研究设计与样本
- 经机构审查委员会批准的多中心前瞻性注册研究,纳入20个具备癌症基因检测与咨询经验的社区和学术站点。
- 纳入既往或新诊断且未接受过单基因或多基因检测的乳腺癌患者,连续入组18至90岁患者并接受80基因panel检测。
- 共入组超过1000例患者,分析959例患者的数据记录。
主要发现
- 49.95%的患者符合NCCN标准,50.05%不符合。
- 总体8.65%的患者携带致病/可能致病(P/LP)变异。
- 符合NCCN指南且有检测结果的患者中9.39%携带P/LP变异,不符合指南的患者中7.9%携带P/LP变异。
- 两组阳性结果差异无统计学意义(Fisher精确检验P=0.4241)。
临床怎么用
- 作者建议所有确诊乳腺癌的患者接受扩大panel检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: An estimated 10% of breast and ovarian cancers result from hereditary causes. Current testing guidelines for germ line susceptibility genes in patients with breast carcinoma were developed to identify carriers of BRCA1/ 2 variants and have evolved in the panel-testing era. We evaluated the capability of the National Comprehensive Cancer Network (NCCN) guidelines to identify patients with breast cancer with pathogenic variants in expanded panel testing. METHODS: An institutional review board-approved multicenter prospective registry was initiated with 20 community and academic sites experienced in cancer genetic testing and counseling. Eligibility criteria included patients with a previously or newly diagnosed breast cancer who had not undergone either single- or multigene testing. Consecutive patients 18 to 90 years of age were consented and underwent an 80-gene panel test. Health Insurance Portability and Accountability Act-compliant electronic case report forms collected information on patient demographics, diagnoses, phenotypes, and test results. RESULTS: More than 1,000 patients were enrolled, and data records for 959 patients were analyzed; 49.95% met NCCN criteria, and 50.05% did not. Overall, 8.65% of patients had a pathogenic/likely pathogenic (P/LP) variant. Of patients who met NCCN guidelines with test results, 9.39% had a P/LP variant. Of patients who did not meet guidelines, 7.9% had a P/LP variant. The difference in positive results between these groups was not statistically significant (Fisher's exact test P = .4241). CONCLUSION: Our results indicate that nearly half of patients with breast cancer with a P/LP variant with clinically actionable and/or management guidelines in development are missed by current testing guidelines. We recommend that all patients with a diagnosis of breast cancer undergo expanded panel testing.
引用
- Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J Clin Oncol. 2018. PMID: 30526229. doi:10.1200/JCO.18.01631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。